Governance of natural health products regulation: An iterative process

Health Policy

Volumn 111, Issue 1, 2013, Pages 86-94

  Walji, Rishma ^a   Wiktorowicz, Mary E ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b York University   (Canada)

Author keywords

Complementary and alternative medicines; Dietary supplements; Governance; Natural health products; Regulation

Indexed keywords

NATURAL PRODUCT; NON PRESCRIPTION DRUG;

ARTICLE; CHINESE MEDICINE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG LEGISLATION; DRUG QUALITY; DRUG SAFETY; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HEALTH CARE PERSONNEL; HUMAN; QUALITATIVE RESEARCH;

EID: 84879845515     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2013.02.011     Document Type: Article

References (38)

1. World Health Organization. WHO traditional medicine strategy 2002-2005. Geneva: World Health Organization; 2002 http://www.who.int/medicines/library/trm/trm strat eng.pdf
2. Guidelines on registration of traditional medicines in the WHO African Region. AFR/TRM/04.1; 2004.
3. Robinson MM, Zhang X. The world medicines situation 2011. In: Traditional medicines: global situation, issues and challenges. Geneva: World Health Organization; 2011.
4. Barnes P, Bloom B. Complementary and alternative medicine use among adults and children: United States, 2007. National health statistics reports, vol. 12; 2008. p. 1-24.
5. World Health Organization. Traditional medicine factsheet; 2008.
6. Ipsos Reid natural health product tracking survey-2010 final report; 2011.
7. Health Canada. A new approach to natural health products. Natural Health Products Directorate; 2012.
8. Government of Canada. Food and drug regulations; 2011.
9. Cole MR, Fetrow CW. Adulteration of dietary supplements. American Journal of Health-System Pharmacy 2003;60(15):1576-80.
10. Lu YL, et al. Detection of adulteration of anti-hypertension dietary supplements and traditional Chinese medicines with synthetic drugs using LC/MS. Food Additives and Contaminants Part A: Chemistry, Analysis, Control, Exposure and Risk Assessment 2010;27(7):893-902.
11. Maughan RJ. Contamination of dietary supplements and positive drug tests in sport. Journal of Sports Sciences 2005;23(9):883-9.
12. Brownie S. The development of the US and Australian dietary supplement regulations. What are the implications for product quality? Complementary Therapies in Medicine 2005;13(3):191-8.
13. Cairns R. Rationales for regulation. Technical report series vol. 2. Ottawa: Economic Council of Canada; 1980.
14. Weimer DL, Vining AR. Policy analysis, concepts and practice. Englewood Cliffs, NJ: Prentice-Hall Inc.; 1989.
15. Dewees DN, Mathewson GF, Trebilcock M. The rationale for government regulation of quality. In: Dewees DN, editor. The regulation of quality: product, services, workplaces and the environment. Toronto: Butterworks; 1983. p. 1-26.
16. Davis P. Pharmaceuticals and public policy: learning from the New Zealand experience. Health Policy 1993;24(3):259-72.
17. Baume P. A question of balance. Report of the failure of drug evaluation in Australia. Canberra: Commonwealth of Australia; 1991.
18. Trebilcock M, Waverman L, Pritchard JRS. Markets for regulation. In: Government regulation, issues and alternatives. Ottawa: Ontario Economic Council; 1978.
19. Dukes MN. The importance of adverse reactions in drug regulation. Drug Safety 1990;5(1):3-6.
20. Mitnick B. The political economy of regulation: creating, designing and removing regulatory forms. New York: Columbia University Press; 1980.
21. Wood DJ. Strategic uses of public policy. Marchfield, MA: Pitman Publishing; 1986.
22. Hancher L, Ruete M. Legal culture, product licensing, and the drug industry. In: Wilks S, Wright M, editors. Comparative government-industry relations: Western Europe, the United States, and Japan. Oxford: Clarendon Press; 1987.
23. Coleman WD, Skogstad G. Policy communities and policy networks: a structural approach. In: Coleman WD, Skogstad G, editors. Policy communities and public policy. Mississauga, Canada: Copp Clark Pitman Ltd.; 1990. p. 14-33.
24. Health Canada. Medeffect; 2011.
25. Government of Canada. Natural health products (Unprocessed Licence Applications) regulations; 2011.
26. Rossi P, Freeman H, Lipsey M. Evaluation, a systematic approach, 6th ed. Thousand Oaks: Sage Publications; 1999.
27. Creswell J. Qualitative inquiry and research design: chosing among five traditions. London: Sage; 1998.
28. Health Canada. Status of applications quarterly report: quarter 2. Ottawa, Canada: Natural Health Products Directorate; 2013.
29. Health Canada. Drug product database; 2013.
30. West S, et al. Systems to rate the strength of scientific evidence. Evidence reports/technology assessments. Rockville, MD: US Agency for Healthcare Research and Quality; 2002.
31. World Health Organization. General guidelines for methodologies on research and evaluation of traditional medicine; 2000.
32. General guidelines for methodologies on research and evaluation of traditional medicine. WHO/EDM/TRM/2000.1; 2000.
33. National policy on traditional medicine and regulation of herbal medicines: report of a WHO global survey; 2005.
34. Vlietinck A, Pieters L, Apers S. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union. Planta Medica 2009;75(7):683-8.
35. Therapeutic Goods Administration. The regulation of complementary medicines in Australia-an overview. D.o.H.a. Ageing; 2007.
36. World Health Organization.Report of the regional meeting on traditional medicine and herbal medicines. 2003.
37. Yada R, Smith MJ. Regulation of natural health products. IUFoST Scientific Information Bulletin (SIB): International Union of Food Science and Technology; 2010.
38. Statistics Canada. Results from the functional foods and natural health products survey; 2007.